These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20634068)

  • 1. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
    Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-oxime inhibitors of B-Raf(V600E) kinase.
    Ren L; Wenglowsky S; Miknis G; Rast B; Buckmelter AJ; Ely RJ; Schlachter S; Laird ER; Randolph N; Callejo M; Martinson M; Galbraith S; Brandhuber BJ; Vigers G; Morales T; Voegtli WC; Lyssikatos J
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1243-7. PubMed ID: 21251822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
    Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.
    Stellwagen JC; Adjabeng GM; Arnone MR; Dickerson SH; Han C; Hornberger KR; King AJ; Mook RA; Petrov KG; Rheault TR; Rominger CM; Rossanese OW; Smitheman KN; Waterson AG; Uehling DE
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4436-40. PubMed ID: 21733693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.
    Lu B; Cao H; Cao J; Huang S; Hu Q; Liu D; Shen R; Shen X; Tao W; Wan H; Wang D; Yan Y; Yang L; Zhang J; Zhang L; Zhang L; Zhang M
    Bioorg Med Chem Lett; 2016 Feb; 26(3):819-823. PubMed ID: 26739779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
    Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
    Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
    Yu M; Yang H; Wu K; Ji Y; Ju L; Lu X
    Bioorg Med Chem; 2014 Aug; 22(15):4109-18. PubMed ID: 24934992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
    Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
    J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
    Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.
    Tang J; Lackey KE; Dickerson SH
    Bioorg Med Chem Lett; 2013 Jan; 23(1):66-70. PubMed ID: 23218715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
    Wenglowsky S; Moreno D; Rudolph J; Ran Y; Ahrendt KA; Arrigo A; Colson B; Gloor SL; Hastings G
    Bioorg Med Chem Lett; 2012 Jan; 22(2):912-5. PubMed ID: 22209462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
    Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
    J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors.
    Xu Z; Yan G; Wang G; Li B; Zhu J; Sun P; Zhang X; Luo C; Wang H; Zhu W
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5428-37. PubMed ID: 22858139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.